Thursday , 5 December 2019
Home » Health » US – FDA : Enanta drug part of hepatitis C priority review
US – FDA : Enanta drug part of hepatitis C priority review
US - FDA : Enanta drug part of hepatitis C priority review

US – FDA : Enanta drug part of hepatitis C priority review

Enanta drug is all set to get hepatitis C priority review. Research based pharmaceuticals company AbbVie Inc. has reported that the US authorities have granted it permission for experimental all-oral test on the hepatitis C patients.

The three direct-acting antiviral investigational regimen consists of the fixed-dose combination of ABT-450/ritonavir (150/100mg) co-formulated with ombitasvir (ABT-267) 25mg, dosed once daily, and dasabuvir (ABT-333) 250mg with or without ribavirin (weight-based), dosed twice daily. ABT-450 is Enanta’s lead protease inhibitor developed through Enanta’s collaboration with AbbVie.

The NDA was submitted on April 21, 2014 and is supported by data from a large clinical program being conducted by AbbVie, including six phase 3 studies of more than 2,300 GT1 patients in over 25 countries. The regimen was granted a Breakthrough Therapy designation by the FDA in May 2013, a status given to investigational treatments for serious or life-threatening conditions with preliminary clinical evidence demonstrating substantial improvement on at least one clinically significant endpoint compared to available therapy.

In May 2014, AbbVie submitted marketing authorization applications (MAAs) for regulatory approval in the European Union.

In addition, Enanta confirmed that in the quarter ending June 30, 2014 it has now received from AbbVie milestone payments totaling $40 million related to these regulatory filings.

Agencies/Canadajournal




  • About News

    Web articles – via partners/network co-ordinators. This website and its contents are the exclusive property of ANGA Media Corporation . We appreciate your feedback and respond to every request. Please fill in the form or send us email to: [email protected]

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    *